there is no bottom, no top... this is small cap momentum-retail trading. anything can happen on any given day.
i guess you missed the CNBC interview... Newlink will have 650,000 doses in the field by end of year.
Forget about Feuerstein & NLNK ~ it's a non-issue. Feuerstein dropped his clip all over the deck when Roche stepped aboard.
Attaran - an assistant prof at Ottawa U - decided to get extra points with his students by writing an open letter to Rona Ambrose, Canada's Health Minister. From the complaints voiced in his letter, Attaran seems to have little understanding of FDA approval process. In the letter he advises Ambrose to weasel out of the Newlink agreement - he makes specific reference to a paltry payment for the license, and "low single digit royalties".
Attaran's list of grievances was slipshod crafted to resonate with Joe Public, but nobody in Canadian government is likely to take him seriously, and Canada will not dishonor its contractual agreement with Newlink. These are merely the ramblings of a of a disaffected professor aspiring to greater things.
my goodness. they are getting stupider. is that even possible?
As far as i know, TKM-Ebola (Tekmira) is not a vaccine ~ it's a therapeutic treatment. A vaccine is a preventative measure designed for large populations that are at risk, but not yet infected. The Tekmira drug would be used on infected victims only. Newlink's VSV-EBOV drug is a vaccine. Apples & oranges.
rampant layered trading now... with every uptick rally, somebody throws a couple of thousand shares onto the ASK a few cents cheaper ~ but irt doesn't seem to be working for them. they just installed another 10K roadblock at $32.87. See if that holds :)
"We are intrigued by the biology of the IDO and TDO compounds and are very interested in the potential to combine them with Genentech's portfolio of novel therapies."
"We certainly think that this might be the case, particularly if you consider NLNK’s recent earnings estimate revision activity. From this look, the company’s future is quite favorable; as NLNK has earned itself a Zacks Rank #2 (Buy), meaning that its recent run may continue for a bit longer, and that this isn’t the top for the in-focus company."
AF influence is substantial on the biotech market, but it doesn't stack up to a hill of beans alongside Roche.